Remove 2005 Remove Healthcare Remove Pharmacology
article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. Expert Review of Clinical Pharmacology. Plant cannabinoids: a neglected pharmacological treasure trove. British journal of pharmacology.

Medical 98
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 Approach taken by regulators in the UK The Medicines and Healthcare products Regulatory Agency regulates herbal medicines in the UK. Only through concerted action can the full potential of botanical medicines be realised, offering new avenues of treatment and wellness to global healthcare landscapes. 2005 [cited 2024May].

Marketing 103
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Active immunotherapy through vaccination has a far lower cost than mAb-based therapies, representing an important decrease of economic burden for healthcare systems at a global scale. She has extensive experience in the biopharmaceutical industry and previously served as Chief Scientific Officer for Novimmune from 2005.